Q2 EPS Forecast for Unicycive Therapeutics Lifted by Analyst

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Brookline Capital Markets increased their Q2 2026 earnings per share estimates for shares of Unicycive Therapeutics in a research report issued on Thursday, May 14th. Brookline Capital Markets analyst K. Raja now forecasts that the company will post earnings per share of ($0.30) for the quarter, up from their previous estimate of ($0.34). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.35) per share. Brookline Capital Markets also issued estimates for Unicycive Therapeutics’ Q3 2026 earnings at ($0.34) EPS and Q4 2026 earnings at ($0.28) EPS.

UNCY has been the subject of several other reports. Benchmark reduced their target price on Unicycive Therapeutics from $21.00 to $15.00 and set a “speculative buy” rating for the company in a research note on Monday, April 6th. Westpark Capital initiated coverage on Unicycive Therapeutics in a research note on Thursday, February 19th. They issued a “buy” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, March 27th. B. Riley Financial initiated coverage on Unicycive Therapeutics in a research note on Friday, May 1st. They issued a “buy” rating and a $22.00 target price for the company. Finally, Wall Street Zen downgraded Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Unicycive Therapeutics Price Performance

Shares of UNCY opened at $8.15 on Tuesday. The stock has a 50-day moving average of $7.15 and a 200-day moving average of $6.43. The company has a market cap of $217.61 million, a PE ratio of -3.69 and a beta of 1.78. Unicycive Therapeutics has a one year low of $3.71 and a one year high of $11.00.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.08).

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Lazard Asset Management LLC bought a new position in shares of Unicycive Therapeutics in the second quarter worth $55,000. JPMorgan Chase & Co. grew its stake in shares of Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after buying an additional 21,525 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Unicycive Therapeutics during the first quarter valued at about $161,000. Citadel Advisors LLC bought a new position in shares of Unicycive Therapeutics during the third quarter valued at about $182,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Unicycive Therapeutics during the fourth quarter worth about $226,000. Institutional investors own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.